Trials / Withdrawn
WithdrawnNCT05156827
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke
A Phase 2 Double-blind, Randomized, Multi-center, Parallel-group Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Patients With Acute Ischemic Stroke
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- TrueBinding, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This multi-center, randomized, parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of TB006 in participants with an Acute Ischemic Stroke (AIS) event with 57 days of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TB006 | TB006 diluted in normal saline, administered through IV infusion over an hour |
| DRUG | Placebo | Normal saline administered through IV infusion over an hour |
Timeline
- Start date
- 2022-07-26
- Primary completion
- 2023-12-18
- Completion
- 2023-12-18
- First posted
- 2021-12-14
- Last updated
- 2024-01-12
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05156827. Inclusion in this directory is not an endorsement.